中华放射肿瘤学杂志
Sunday, Apr. 6, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2023, Vol. 32 Issue (7): 584-591    DOI: 10.3760/cma.j.cn113030-20220902-00297
Thoracic Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Prognostic impacts of the estimated dose of radiation to immune cells (EDRIC) on limited-stage small-cell lung cancer with different tumor burdens
Lai Jianian, Guan Song, Yan Meng, Meng Chunliu, Zhang Zhen, Zhang Jiaqi, Zhao Lujun
Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Objective To investigate the effects of estimated dose of radiation to immune cells (EDRIC) on overall survival (OS), local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) in limited-stage small-cell lung cancer (LS-SCLC) with different tumor burdens. Methods Clinical data of 216 patients with LS-SCLC who initially received conventional fractionated radiotherapy of the chest for radical treatment in Tianjin Medical University Cancer Institute and Hospital from 2013 to 2019 were retrospectively analyzed. EDRIC was calculated based on the model developed by Jin et al. and tumor burdens were assessed by gross tumor volume (GTV) or clinical stage. The study endpoints were OS, LPFS and DMFS, which were calculated from the date of diagnosis. The optimal cut-off value of EDRIC was calculated by R language. The correlation between EDRIC and tumor burdens was analyzed using Spearman's correlations. Survival analysis was performed by Cox proportional hazards regression model and Kaplan-Meier curve. Results The median follow-up time for the whole group was 47.8 months, and the median OS and DMFS was 34.6 months and 18.5 months, respectively, while the median LPFS did not reach. The optimal cut-off value of EDRIC was 6.8 Gy. Cox multivariate analysis showed that EDRIC was an independent prognostic factor affecting OS and DMFS. EDRIC was weakly correlated with GTV or clinical stage. Stratified by the median GTV, OS (P=0.021) and DMFS (P=0.030) were significantly shortened and LPFS had a tendency of shortening (P=0.107) when EDRIC>6.8 Gy compared with those when EDRIC ≤ 6.8 Gy in the GTV ≤ 34.6 cm3 group; EDRIC had little effect on OS, LPFS, and DMFS (P=0.133, 0.420, 0.374) in the GTV>34.6 cm3 group. Stratified by clinical stage, OS (P=0.003) and DMFS (P=0.032) were significantly shortened and LPFS (P=0.125) tended to shorten when EDRIC>6.8 Gy in stage I, II and IIIA groups; EDRIC exerted slight effect on OS, LPFS, and DMFS (P=0.377, 0.439, 0.484) in stage IIIB and IIIC groups. Conclusion EDRIC is an important factor affecting prognosis and exerts more significant impact on prognosis in patients with smaller tumor burden.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Lai Jianian
Guan Song
Yan Meng
Meng Chunliu
Zhang Zhen
Zhang Jiaqi
Zhao Lujun
Key wordsSmall cell lung carcinoma      Estimated dose of radiation to immune cells      Tumor burden      Prognosis     
Received: 02 September 2022     
Corresponding Authors: Zhao Lujun, Email: zhaolujun@tjmuch.com   
Cite this article:   
Lai Jianian,Guan Song,Yan Meng et al. Prognostic impacts of the estimated dose of radiation to immune cells (EDRIC) on limited-stage small-cell lung cancer with different tumor burdens[J]. Chinese Journal of Radiation Oncology, 2023, 32(7): 584-591.
Lai Jianian,Guan Song,Yan Meng et al. Prognostic impacts of the estimated dose of radiation to immune cells (EDRIC) on limited-stage small-cell lung cancer with different tumor burdens[J]. Chinese Journal of Radiation Oncology, 2023, 32(7): 584-591.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20220902-00297     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2023/V32/I7/584
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn